logo-loader
viewMicrobot Medical Inc

Microbot Medical shares pop on clinching of new European patent

The micro-robotic medical technology company has won a European patent for its ViRob technology platform, which is an autonomous crawling micro-robot that can navigate and crawl in different spaces within the body

depiction of body on screen
The miniature dimensions of Microbot's ViRob technology allow it to navigate and crawl in different spaces within the body

Shares of Microbot Medical Inc (NASDAQ:MBOT) almost doubled in Monday’s pre-market session after the micro-robotic medical technology company clinched a European patent for its ViRob technology platform.

The European Patent Office has granted a patent which covers Microbot’s autonomous crawling micro-robot which can be controlled remotely or within the body.

READ: Microbot Medical shares rise 10% on patent news

The new approval by European regulators means the Hingham, Massachusetts-based company now has 30 issued patents and 18 patent applications pending.

“The allowance of this European patent application further strengthens our global intellectual property estate covering our micro-robotic technology platform,” said CEO Harel Gadot.

Investors applauded the news, sending Microbot shares up 69.6% to $4.07 before the opening bell on Monday.

Microbot, which was set up in 2010 and kicked off operations in 2011, went public on Nasdaq in November 2016. The company specializes in micro-robotic medical technologies, leveraging the natural and artificial lumens within the body. 

The miniature dimensions of Microbot’s ViRob technology allow it to navigate and crawl in different spaces within the body, including blood vessels, the digestive tract and the respiratory system. It has the ability to move in tight spaces and curved passages as well as the ability to remain within the body for a prolonged period of time.

Contact Ellen Kelleher at [email protected]

Quick facts: Microbot Medical Inc

Price: 7.97 USD

NASDAQ:MBOT
Market: NASDAQ
Market Cap: $56.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arcadia Biosciences reports strong 2Q revenue despite coronavirus impact

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Matthew Plavan tells Proactive the California-based group's 2Q revenue growth was fueled by GLA sales and GoodWheat royalties. Plavan says the company also cinched a trio of recent GoodWheat agreements: a collaboration with Corner Foods to bring its...

11 hours, 43 minutes ago

2 min read